Beigene (BGNE) Earns News Impact Score of 0.20
News coverage about Beigene (NASDAQ:BGNE) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Beigene earned a news impact score of 0.20 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.3978592085663 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- University of Notre Dame DU Lac Cuts Position in Beigene Ltd (BGNE) (americanbankingnews.com)
- Ladenburg Thalmann Financial Services Reiterates Buy Rating for Beigene (BGNE) (americanbankingnews.com)
- Beigene Ltd (BGNE) Holdings Cut by The Manufacturers Life Insurance Company (americanbankingnews.com)
- China’s Tasly to list biotech arm in $1 bln Hong Kong IPO – sources (finance.yahoo.com)
- Beigene Ltd (BGNE) Forecasted to Post Q1 2018 Earnings of ($1.87) Per Share (americanbankingnews.com)
Shares of Beigene (NASDAQ BGNE) traded up $1.68 during trading hours on Friday, reaching $151.97. 341,285 shares of the company were exchanged, compared to its average volume of 381,984. The company has a market capitalization of $8,020.00 and a P/E ratio of -63.85. Beigene has a 52 week low of $34.36 and a 52 week high of $164.15. The company has a quick ratio of 6.02, a current ratio of 6.09 and a debt-to-equity ratio of 0.23.
BGNE has been the topic of a number of research reports. Maxim Group set a $120.00 price target on Beigene and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Cowen reissued a “buy” rating on shares of Beigene in a research note on Tuesday, November 14th. Finally, BidaskClub raised shares of Beigene from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Beigene presently has a consensus rating of “Buy” and an average target price of $127.67.
In other news, CMO Jane Huang sold 1,500 shares of the company’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $94.25, for a total transaction of $141,375.00. Following the transaction, the chief marketing officer now directly owns 1,500 shares of the company’s stock, valued at $141,375. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John Oyler sold 20,137 shares of the company’s stock in a transaction on Tuesday, December 26th. The stock was sold at an average price of $96.46, for a total value of $1,942,415.02. Following the transaction, the chief executive officer now directly owns 110,179 shares in the company, valued at $10,627,866.34. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 165,975 shares of company stock worth $23,105,001. Insiders own 19.90% of the company’s stock.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.